"Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative" Pharmacodynamics, Pharmacokinetics and Pharmacogenomics study
Latest Information Update: 24 Aug 2017
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- 22 Aug 2017 Status changed from active, no longer recruiting to completed.
- 25 Mar 2016 Status changed from recruiting to active, no longer recruiting.
- 12 Oct 2015 New trial record